Stock AnalizMetlife Inc. MET
Life Insurance · IPO 2000 · data as of November 13, 2026
Metlife Inc. (MET) is a financial company listed in the US with a market value of about $64.5B. In the twelve months to September 30, 2026 it had revenue of $82.6B and net income of $5.0B, a net margin of 6.0%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is shareholder returns (5/5); the weakest is future growth (1/5).
Key numbers: a P/E of 13.4, a price to free cash flow of 4.6, 5-year revenue growth of 3% a year, a 5-year average ROIC of 10%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 3% above the current price.
Score: 2.8 / 5
Checks passed
- P/E below 25
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.6B | $77.1B | $71.0B | $66.9B | $68.8B | $68.7B | $67.8B | $69.6B | $67.9B | $62.3B | $60.8B |
| Net income | $5.0B | $3.4B | $4.4B | $1.6B | $5.3B | $6.9B | $5.4B | $5.9B | $5.1B | $4.0B | $850M |
| Free cash flow | $14.0B | $17.1B | $14.6B | $13.7B | $13.0B | $12.3B | $11.6B | $13.8B | $11.7B | $12.3B | $14.8B |
| EPS (diluted) | $7.67 | $4.71 | $5.94 | $1.81 | $6.30 | $7.65 | $5.68 | $6.06 | $4.91 | $3.62 | $0.67 |
| Net margin | 6.0% | 4.4% | 6.2% | 2.4% | 7.7% | 10.0% | 8.0% | 8.5% | 7.5% | 6.4% | 1.4% |
| ROIC | — | 10.2% | 10.9% | 9.1% | 10.9% | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 16 analysts is $111.12, 8% above the current price; targets range from $84.00 to $131.00; the consensus rating is “Buy”; expected EPS is $10.23 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Metlife’s P/E ratio?
About 13.4, based on the last twelve months of diluted earnings per share (forward P/E about 9.5).
Is Metlife stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 3% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Metlife pay a dividend?
Yes. The dividend yield is about 2.31%, and it has paid dividends for 10 years in our data.
Is Metlife a good stock to buy?
We do not give buy or sell advice. Metlife scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.